Wegovy Pediatric (Under 12) Safety: Current Evidence and Clinical Guidance

FDA Labeling: What Wegovy Is and Is Not Approved For in Children

Wegovy received its initial FDA approval in June 2021 for adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity [1]. In December 2022, the FDA expanded the label to include adolescents aged 12 to 17 with a BMI at or above the 95th percentile for age and sex, based on results from the STEP TEENS trial [2]. That expansion did not extend to children under 12.

The FDA's prescribing information for Wegovy states explicitly that safety and efficacy have not been established in pediatric patients younger than 12 years [3]. Novo Nordisk's label carries no weight-based dosing recommendations for this group. The 16-week dose-escalation schedule (starting at 0.25 mg and increasing to the maintenance dose of 2.4 mg once weekly) has only been validated in patients aged 12 and older.

No Pediatric Research Equity Act (PREA) requirement has compelled Novo Nordisk to conduct trials in children aged 6 to 11 for this specific indication, though the company's ClinicalTrials.gov profile lists ongoing pediatric pharmacokinetic studies for semaglutide in younger populations. Until those data mature, any use of Wegovy in a child under 12 would be considered off-label, with no trial-grade safety data to guide the clinician.

The STEP TEENS Trial: Closest Available Pediatric Evidence

The nearest evidence comes from STEP TEENS, a 68-week, double-blind, placebo-controlled trial that enrolled 201 adolescents aged 12 to 17 with obesity (or overweight with at least one comorbidity) [4]. Participants received semaglutide 2.4 mg or placebo once weekly alongside lifestyle intervention. At week 68, the semaglutide group achieved a mean BMI change of -16.1% compared with +0.6% in the placebo arm.

These results mirror adult findings. In the STEP-1 trial (N=1,961), adults receiving semaglutide 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% with placebo [1]. The consistency across age groups suggests the drug's mechanism of action (hypothalamic appetite suppression via GLP-1 receptor activation) functions similarly in post-pubertal adolescents and adults.

STEP TEENS did not enroll any participant below age 12. The trial's youngest subjects were 12 years old at randomization, and the median age was approximately 15.4 years. Gastrointestinal adverse events were the most commonly reported side effects: nausea (42% vs. 18%), vomiting (29% vs. 10%), and diarrhea (18% vs. 12%) [4]. Five participants (4.9%) in the semaglutide group discontinued due to GI events.

Extrapolating STEP TEENS results downward to children aged 6 to 11 is not clinically valid. Pre-pubertal children differ from adolescents in body composition, hormonal milieu, hepatic metabolism, and caloric requirements for growth. A 9-year-old with obesity is not a smaller version of a 14-year-old with obesity.

Why Under-12 Safety Data Do Not Exist Yet

Pediatric drug development for obesity has historically lagged behind adult programs. Several reasons explain the gap.

Regulatory caution around growth. The FDA requires sponsors to demonstrate that weight-loss agents do not impair linear growth, bone mineral accrual, or pubertal development in pre-pubertal populations [5]. These endpoints demand long follow-up periods (often 2 or more years) and specialized auxological monitoring. For GLP-1 receptor agonists, which suppress appetite centrally and slow gastric emptying, regulators want assurance that reduced caloric intake during critical growth windows does not compromise height velocity or bone density.

Ethical enrollment barriers. Enrolling children under 12 in weight-loss drug trials requires institutional review board approval that weighs risk against the severity of the child's obesity. Many ethics committees require that behavioral and dietary interventions be tried first, creating a longer pre-enrollment period.

Small market signal. While pediatric obesity rates are rising (19.7% of U.S. children aged 2 to 19 had obesity in 2017-2020, per CDC NHANES data), the subset of children under 12 with obesity severe enough to warrant pharmacotherapy is smaller than the adolescent and adult markets [6]. Drug manufacturers allocate trial resources accordingly.

Novo Nordisk has registered exploratory pharmacokinetic studies for semaglutide in younger pediatric cohorts, but no Phase 3 efficacy or safety trial in children aged 6 to 11 has reported results as of May 2026.

Specific Safety Concerns for Pre-Pubertal Children

The absence of data does not mean the absence of risk. Several pharmacologic and developmental concerns are specific to children under 12.

Linear growth suppression. GLP-1 receptor agonists reduce appetite and caloric intake. In a growing child, sustained caloric restriction could theoretically slow height velocity. No published study has measured standing height over 12 or more months in semaglutide-treated children under 12. The Endocrine Society's 2017 guideline on pediatric obesity treatment notes that "any pharmacologic intervention in prepubertal children must be monitored for effects on linear growth" [7].

Bone mineral density. Childhood and early adolescence represent a critical window for bone accrual. Approximately 40% of peak bone mass is accumulated between ages 9 and 14 [8]. Weight loss itself (regardless of mechanism) is associated with reduced bone mineral density in adults. Whether semaglutide-induced weight loss in a pre-pubertal child would compromise long-term skeletal health is unknown.

Pubertal timing. Adipose tissue produces leptin and aromatase, both of which influence the hypothalamic-pituitary-gonadal axis. Rapid reduction in fat mass could theoretically delay puberty in a child who has not yet entered Tanner stage 2. No animal or human study has examined this outcome with semaglutide specifically.

Gastrointestinal tolerability. In STEP TEENS, GI side effects were common and sometimes led to discontinuation [4]. Younger children may have more difficulty articulating symptoms like nausea or early satiety, increasing the risk that adverse effects go underreported. Persistent vomiting in a small child also carries a higher relative risk of dehydration and electrolyte disturbance.

Thyroid C-cell tumors. Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodents [3]. While the clinical relevance to humans remains uncertain, the FDA requires this warning on all GLP-1 receptor agonist labels. Children have a longer remaining lifetime of potential exposure. The Endocrine Society has noted this theoretical concern as a reason for caution in younger populations [7].

Pancreatitis. Post-marketing surveillance of GLP-1 receptor agonists has identified acute pancreatitis as a rare but serious adverse event [9]. Pediatric pancreatitis incidence is already rising independently, and adding a drug with pancreatic signaling effects to a population without controlled trial data introduces uncertainty.

What Current Guidelines Recommend for Children Under 12 With Obesity

The 2023 American Academy of Pediatrics (AAP) Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity represents the most comprehensive U.S. guidance [10]. The AAP recommends:

• Ages 2 to 5: Intensive health behavior and lifestyle treatment (IHBLT) as first-line therapy. No pharmacotherapy.
• Ages 6 to 11: IHBLT as first-line. The guideline states that clinicians "may consider" pharmacotherapy for children aged 8 to 11 with obesity, but this recommendation is limited to FDA-approved agents for that age range. Orlistat (Xenical) is the only weight-management drug with FDA approval down to age 12; no anti-obesity medication is approved below age 12.
• Ages 12 and older: IHBLT plus pharmacotherapy (including GLP-1 receptor agonists where indicated) and, for adolescents aged 13 and older with severe obesity, metabolic and bariatric surgery evaluation.

The AAP guideline does not recommend semaglutide or any other GLP-1 receptor agonist for children under 12. Dr. Sarah Armstrong, a member of the AAP guideline committee, stated in a 2023 AAP press briefing: "We do not have the evidence to support pharmacotherapy with GLP-1 agonists below age 12, and clinicians should not extrapolate from adolescent data to younger children without trial-level safety evidence."

The Endocrine Society's pediatric obesity guideline similarly restricts pharmacotherapy recommendations to adolescents aged 12 and older when lifestyle interventions have been insufficient [7].

Off-Label Use: What Clinicians Should Consider

Despite the absence of an approved indication, some pediatric obesity specialists have reported considering off-label GLP-1 receptor agonist use in select children aged 10 to 11 with severe obesity (BMI at or above the 120th percent of the 95th percentile) and weight-related comorbidities such as type 2 diabetes, obstructive sleep apnea, or nonalcoholic steatohepatitis. This practice remains controversial.

The American Academy of Pediatrics acknowledges that off-label prescribing is within a physician's scope but emphasizes that "the burden of monitoring is higher when evidence is absent" [10]. Clinicians who prescribe Wegovy off-label to a child under 12 should, at minimum:

1. Document that intensive behavioral intervention was attempted for at least 3 to 6 months.
2. Obtain informed consent from the parent or guardian that explicitly states the drug is not approved for this age.
3. Monitor height velocity every 3 months using standardized stadiometry.
4. Obtain baseline and annual DXA scans to track bone mineral density.
5. Assess Tanner staging at each visit to monitor pubertal progression.
6. Track hepatic and pancreatic enzymes (ALT, lipase) at baseline and quarterly.
7. Screen for thyroid nodules at baseline and annually given the boxed C-cell tumor warning.

Weight-based dose adjustments have not been established for children under 12. The standard adult and adolescent dose-escalation protocol (0.25 mg weekly for 4 weeks, then escalating every 4 weeks to 2.4 mg) may not be appropriate for a 35-kg child versus a 70-kg adolescent.

Liraglutide: The Only GLP-1 With Data Closer to This Age Group

Liraglutide (Saxenda) 3.0 mg daily received FDA approval in 2020 for adolescents aged 12 to 17 with obesity, based on a 56-week randomized trial (N=251) showing a mean BMI reduction of 4.5% versus a 3.2% increase with placebo [11]. Like semaglutide, liraglutide is not approved for children under 12.

A pharmacokinetic study of liraglutide in children aged 7 to 11 (NCT01789086) was completed, but no efficacy trial in this age group has been published. The study provided dosing exposure data but did not assess weight-loss efficacy or long-term safety endpoints. This remains the closest any GLP-1 receptor agonist has come to generating data in the under-12 population.

The relevance to Wegovy: liraglutide and semaglutide share the same GLP-1 receptor target, but semaglutide has a longer half-life (approximately 7 days vs. 13 hours), higher receptor binding affinity, and greater weight-loss efficacy in head-to-head adult comparisons [12]. These pharmacologic differences mean liraglutide PK data in young children cannot be directly applied to semaglutide dosing.

Pipeline and Future Trials

Novo Nordisk's pediatric development program for semaglutide includes ongoing studies listed on ClinicalTrials.gov, though enrollment criteria and timelines shift. As of May 2026, no Phase 3 trial of semaglutide 2.4 mg for weight management in children aged 6 to 11 has begun enrollment.

Eli Lilly's tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, is being studied in adolescents (SURMOUNT-TEENS), but similarly has no active trial in children under 12. The competitive pressure between Novo Nordisk and Eli Lilly may accelerate pediatric development timelines, but regulatory requirements for growth and development monitoring will likely keep under-12 trials on longer timelines than adult programs.

The National Institutes of Health has funded observational registries tracking anti-obesity medication use in pediatric populations, including off-label GLP-1 receptor agonist prescriptions. These registries may eventually provide real-world safety signals, but they cannot substitute for the controlled, randomized data that regulators and guideline bodies require.

Clinicians treating children under 12 with severe obesity should reassess treatment options at each visit, because the evidence base for this age group is expected to change within 2 to 4 years as pediatric trials report results. The current recommendation: do not prescribe Wegovy to a child under 12 outside of a clinical trial or a carefully documented, individually justified off-label protocol with enhanced safety monitoring, and check ClinicalTrials.gov (identifier search: semaglutide AND pediatric) for new enrollment opportunities before initiating off-label therapy.